ABCA1 and atherosclerosis

Vascular Medicine

Volumn 10, Issue 2, 2005, Pages 109-119

  Soumian, Soni ^a   Albrecht, C ^b   Davies, A H ^a   Gibbs, R G J ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Apolipoprotein A1; Atherosclerosis; ATP binding cassette transporter 1; HDL cholesterol; Tangier disease

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN A1; CALPAIN; CHOLESTEROL; CLOFIBRATE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER X RECEPTOR ALPHA; MATRIX METALLOPROTEINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOLIPID; PRAVASTATIN; PROTEINASE INHIBITOR; PYRIDINE DERIVATIVE; VERAPAMIL;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL TRANSPORT; ENZYME INHIBITION; GENE FUNCTION; GENE INTERACTION; GENE MUTATION; HETEROZYGOSITY; HOMEOSTASIS; HUMAN; IN VITRO STUDY; INFLAMMATION; LIPID TRANSPORT; LIPOPROTEIN METABOLISM; MEDICAL LITERATURE; MEDLINE; METABOLIC REGULATION; MICROENVIRONMENT; NONHUMAN; ONSET AGE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; REVIEW; TANGIER DISEASE;

ANIMALS; ARTERIOSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; CHOLESTEROL, HDL; DISEASE PROGRESSION; FEMALE; GENETIC MARKERS; HUMANS; MALE; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TANGIER DISEASE; THIAZOLIDINEDIONES;

EID: 21244503531     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1191/1358863x05vm593ra     Document Type: Review

References (127)

1. Tabas I. Cholesterol and phospholipid metabolism in macrophages. Biochim Biophys Acta 2000; 1529: 164-74.
2. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-24.
3. Simons K. How cells handle cholesterol. Science 2000; 290: 1721-26.
4. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995; 36: 211-28.
5. Oram JF, Lawn RM. ABCA1: The gatekeeper for eliminating excess tissue cholesterol. J Lipid Res 2001; 42: 1173-79.
6. Bodzioch M, Orso E, Klucken J et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 1999; 22: 347-51.
7. Oram JF. Tangier disease and ABCA1. Biochim Biophys Acta 2000; 1529: 321-30.
8. Clee SM, Kastelein JJ, van Dam M et al. Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. J Clin Invest 2000; 106: 1263-70.
9. Hamon Y, Broccardo C, Chambenoit O et al. ABC1 promotes engulfment of apoptotic cells and transbilayer redistribution of phosphatidylserine. Nat Cell Biol 2000; 2: 399-406.
10. Reddy ST. ATP-binding cassette transporter 1 participates in LDL oxidation by artery wall cells. Arterioscler Thromb Vasc Biol 2002; 22: 1877-83.
11. Hamon Y, Luciani MF, Becq F, Verrier B, Rubartelli A, Chimini G. Interleukin-1beta secretion is impaired by inhibitors of the ATP binding cassette transporter, ABC1. Blood 1997; 90: 2911-15.
12. Zhou X, Engel T, Goepfert C, Erren M, Assmann G, von Eckardstein A. The ATP binding cassette transporter A1 contributes to the secretion of interleukin 1beta from macrophages but not from monocytes. Biochem Biophys Res Commun 2002; 291: 598-604.
13. Remaley AT, Stonik JA, Demosky SJ et al. Apolipoprotein specificity for lipid efflux by the human ABCAI transporter. Biochem Biophys Res Commun 2001; 280: 818-23.
14. Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 2001; 42: 1007-17.
15. Santamarina-Fojo S, Peterson K, Knapper C et al. Complete genomic sequence of the human ABCA1 gene: analysis of the human and mouse ATP-binding cassette A promoter. Proc Natl Acad Sci U S A 2000; 97: 7987-92.
16. Wang N, Silver DL, Costet P, Tall AR. Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1. J Biol Chem 2000; 275: 33053-58.
17. Neufeld EB, Remaley AT, Demosky SJ et al. Cellular localization and trafficking of the human ABCA1 transporter. J Biol Chem 2001; 276: 27584-90.
18. Fitzgerald ML, Morris AL, Rhee JS, Andersson LP, Mendez AJ, Freeman MW. Naturally occurring mutations in the largest extracellular loops of ABCA1 can disrupt its direct interaction with apolipoprotein A-I. J Biol Chem 2002; 277: 33178-87.
19. Langmann T, Klucken J, Reil M et al. Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): evidence for sterol-dependent regulation in macrophages. Biochem Biophys Res Commun 1999; 257: 29-33.
20. Lawn RM. Localization of human ATP-binding cassette transporter 1 (ABC1) in normal and atherosclerotic tissues. Arterioscler Thromb Vasc Biol 2001; 21: 378-85.
21. Wellington CL. ABCA1 mRNA and protein distribution patterns predict multiple different roles and levels of regulation. Lab Invest 2002; 82: 273-83.
22. Zha X, Gauthier A, Genest J, McPherson R. Secretory vesicular transport from the golgi is altered during ATP-binding cassette protein A1 (ABCA1)-mediated cholesterol efflux. J Biol Chem 2003; 278: 10002-05.
23. Smith JD, Le Goff W, Settle M et al. ABCA1 mediates concurrent cholesterol and phospholipid efflux to apolipoprotein A-I. J Lipid Res 2004; 45: 635-44.
24. Wang N. Regulation and mechanisms of ATP-binding cassette transporter A1-mediated cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 2003; 23: 1178-84.
25. Yancey PG, Kawashiri MA, Moore R et al. In vivo modulation of HDL phospholipid has opposing effects on SR-BI- and ABCA1-mediated cholesterol efflux. J Lipid Res 2004; 45: 337-46.
26. Oram JF, Yokoyama S. Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. J Lipid Res 1996; 37: 2473-91.
27. Chroni A, Liu T, Fitzgerald ML, Freeman MW, Zannis VI. Cross-linking and lipid efflux properties of ApoA-I mutants suggest direct association between ApoA-I helices and ABCA1. Biochemistry 2004; 43: 2126-39.
28. Walter M, Forsyth NR, Wright WE, Shay JW, Roth MG. The establishment of telomerase-immortalized Tangier disease cell lines indicates the existence of an apolipoprotein A-I-inducible but ABCA1-independent cholesterol efflux pathway. J Biol Chem 2004; 279: 20866-73.
29. Gillotte KL, Zaiou M, Lund-Katz S et al. Apolipoprotein-mediated plasma membrane microsolubilization. Role of lipid affinity and membrane penetration in the efflux of cellular cholesterol and phospholipid. J Biol Chem 1999; 274: 2021-28.
30. Fielding PE, Nagao K, Hakamata H, Chimini G, Fielding CJ. A two-step mechanism for free cholesterol and phospholipid efflux from human vascular cells to apolipoprotein A-1. Biochemistry 2000; 39: 14113-20.
31. Wang N, Silver DL, Thiele C, Tall AR. ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein. J Biol Chem 2001; 276: 23742-47.
32. Chambenoit O, Hamon Y, Marguet D, Rigneault H, Rosseneu M, Chimini G. Specific docking of apolipoprotein A-I at the cell surface requires a functional ABCA1 transporter. J Biol Chem 2001; 276: 9955-60.
33. Smith JD, Waelde C, Horwitz A, Zheng P. Evaluation of the role of phosphatidylserine translocase activity in ABCA1-mediated lipid efflux. J Biol Chem 2002; 277: 17797-803.
34. Fitzgerald ML, Morris AL, Chroni A, Mendez AJ, Zannis VI, Freeman MW. ABCA1 and amphipathic apolipoproteins form high-affinity molecular complexes required for cholesterol efflux. J Lipid Res 2004; 45: 287-94.
35. Panagotopulos SE, Witting SR, Horace EM, Hui DY, Maiorano JN, Davidson WS. The role of apolipoprotein A-I helix 10 in apolipoprotein-mediated cholesterol efflux via the ATP-binding cassette transporter ABCA1. J Biol Chem 2002; 277: 39477-84.
36. Marcil M, Brooks-Wilson A, Clee S. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet 1999; 354: 1341-46.
37. Francis GA, Knopp RH, Oram JF. Defective removal of cellular cholesterol and phospholipids by apolipoprotein A-I in Tangier disease. J Clin Invest 1995; 96: 78-87.
38. Moore RE. Apolipoprotein A-I deficiency results in markedly increased atherosclerosis in mice lacking the LDL receptor. Arterioscler Thromb Vasc Biol 2003; 23: 1914-20.
39. Navab M, Hama SY, Cooke CJ et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 2000; 41: 1481-94.
40. Navab M, Hama SY, Anantharamaiah GM et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 2000; 41: 1495-508.
41. Hyka N, Dayer JM, Modoux C et al. Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 2001; 97: 2381-89.
42. Aiello RJ. ABCA1-deficient mice: insights into the role of monocyte lipid efflux in HDL formation and inflammation. Arterioscler Thromb Vasc Biol 2003; 23: 972-80.
43. Virmani R. Lessons from sudden coronary death: A comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20: 1262-75.
44. Ross R. Mechanisms of disease: atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
45. Mathiesen EB, Bonaa KH, Joakimsen O. Low levels of high-density lipoprotein cholesterol are associated with echolucent carotid artery plaques: The Tromso study. Stroke 2001; 32: 1960-65.
46. Mathiesen EB, Bonaa KH, Joakimsen O. Echolucent plaques are associated with high risk of ischemic cerebrovascular events in carotid stenosis: The Tromso study. Circulation 2001; 103: 2171-75.
47. Alagona C. Low HDL cholesterol concentration is associated with increased intima-media thickness independent of arterial stiffness in healthy subjects from families with low HDL cholesterol. Eur J Clin Invest 2003; 33: 457-63.
48. Kiss RS, McManus DC, Franklin V et al. The lipidation by hepatocytes of human apolipoprotein A-I occurs by both ABCA1-dependent and -independent pathways. J Biol Chem 2003; 278: 10119-27.
49. Liu L, Bortnick AE, Nickel M et al. Effects of apolipoprotein A-I on ATP-binding cassette transporter A1-mediated efflux of macrophage phospholipid and cholesterol: formation of nascent high density lipoprotein particles. J Biol Chem 2003; 278: 42976-84.
50. Cavelier LB, Qiu Y, Bielicki JK, Afzal V, Cheng JF, Rubin EM. Regulation and activity of the human ABCA1 gene in transgenic mice. J Biol Chem 2001; 276: 18046-51.
51. Singaraja RR, Bocher V, James ER et al. Human ABCA1 BAC transgenic mice show increased high density lipoprotein cholesterol and ApoAI-dependent efflux stimulated by an internal promoter containing liver X receptor response elements in intron 1. J Biol Chem 2001; 276: 33969-79.
52. Singaraja RR, Fievet C, Castro G et al. Increased ABCA1 activity protects against atherosclerosis. J Clin Invest 2002; 110: 35-42.
53. Vaisman BL, Lambert G, Amar M et al. ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. J Clin Invest 2001; 108: 303-309.
54. Poernama F, Schreyer SA, Bitgood JJ, Cook ME, Attie AD. Spontaneous high density lipoprotein deficiency syndrome associated with a Z-linked mutation in chickens. J Lipid Res 1990; 31: 955-63.
55. Schreyer SA, Hart LK, Attie AD. Hypercatabolism of lipoprotein-free apolipoprotein A-I in HDL-deficient mutant chickens. Arterioscler Thromb 1994; 14: 2053-59.
56. Schaefer EJ, Zech LA, Schwartz DE, Brewer Jr HB. Coronary heart disease prevalence and other clinical features in familial high-density lipoprotein deficiency (Tangier disease). Ann Intern Med 1980; 93: 261-66.
57. van Dam MJ, de Groot E, Clee SM et al. Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study. Lancet 2002; 359: 37-42.
58. Aiello RJ. Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. Arterioscler Thromb Vasc Biol 2002; 22: 630-37.
59. Haghpassand M, Bourassa P-A. Monocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels. J Clin Invest 2001; 108: 1315-20.
60. van Eck M, Bos IS, Kaminski WE et al. Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues. Proc Natl Acad Sci U S A 2002; 99: 6298-303.
61. Sahoo D, Trischuk TC, Chan T et al. ABCA1-dependent lipid efflux to apolipoprotein A-I mediates HDL particle formation and decreases VLDL secretion from murine hepatocytes. J Lipid Res 2004; 45: 1122-31.
62. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 1992; 148: 2207-16.
63. Mallat Z, Hugel B, Ohan J, Leseche G, Freyssinet JM, Tedgui A. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation 1999; 99: 348-53.
64. Wang J, Weiss I, Svoboda K, Kwaan H. Thrombogenic role of cells undergoing apoptosis. Br J Haematol 2001; 115: 382-91.
65. Buechler C, Bared SM, Aslanidis C, Ritter M, Drobnik W, Schmitz G. Molecular and functional interaction of the ATP-binding cassette transporter A1 with Fas-associated death domain protein. J Biol Chem 2002; 277: 41307-10.
66. Rosklint T. Oxysterols induce interleukin-1[beta] production in human macrophages. Eur J Clin Invest 2002; 32: 35-42.
67. Napoli C, Quehenberger O, De Nigris F, Abete P, Glass CK, Palinski W. Mildly oxidized low density lipoprotein activates multiple apoptotic signaling pathways in human coronary cells. Faseb J 2000; 14: 1996-2007.
68. Kellner-Weibel G, Luke SJ, Rothblat GH. Cytotoxic cellular cholesterol is selectively removed by apoA-I via ABCA1. Atherosclerosis 2003; 171: 235-43.
69. Schaub FJ, Han DK, Liles WC et al. Fas/FADD-mediated activation of a specific program of inflammatory gene expression in vascular smooth muscle cells. Nat Med 2000; 6: 790-96.
70. Baranova I, Vishnyakova T, Bocharov A et al. Lipopolysaccharide down regulates both scavenger receptor B1 and ATP binding cassette transporter A1 in RAW cells. Infect Immun 2002; 70: 2995-3003.
71. Panousis CG, Zuckerman SH. Interferon-gamma induces downregulation of Tangier disease gene (ATP- binding-cassette transporter 1) in macrophage-derived foam cells. Arterioscler Thromb Vasc Biol 2000; 20: 1565-71.
72. Ruan XZ. PPAR agonists protect mesangial cells from interleukin 1[beta]-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway. J Am Soc Nephrol 2003; 14: 593-600.
73. Wang XQ, Panousis CG, Alfaro ML, Evans GF, Zuckerman SH. Interferon-gamma-mediated downregulation of cholesterol efflux and ABC1 expression is by the Stat1 pathway. Arterioscler Thromb Vasc Biol 2002; 22: e5-e9.
74. Khovidhunkit W, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. Endotoxin down-regulates ABCG5 and ABCG8 in mouse liver and ABCA1 and ABCG1 in J774 murine macrophages: differential role of LXR. J Lipid Res 2003; 44: 1728-36.
75. Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994; 94: 437-44.
76. Bergt C, Pennathur S, Fu X et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci U S A 2004; 101: 13032-37.
77. Flieger O, Engling A, Bucala R, Lue H, Nickel W, Bernhagen J. Regulated secretion of macrophage migration inhibitory factor is mediated by a non-classical pathway involving an ABC transporter. FEBS Lett 2003; 551: 78-86.
78. Tunon J, Ruiz-Ortega M, Egido J. Regulation of matrix proteins and impact on vascular structure. Curr Hypertension Rep 2000; 2: 106-13.
79. Faia KL, Davis WP, Marone AJ, Foxall TL. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in hamster aortic atherosclerosis: Correlation with in-situ zymography. Atherosclerosis 2002; 160: 325-37.
80. Libby P, Geng YJ, Aikawa M et al. Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol 1996; 7: 330-35.
81. Loftus IM, Naylor AR, Goodall S et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke 2000; 31: 40-47.
82. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: The good, the bad, and the ugly. Circulation Research 2002; 90: 251-62.
83. Ruhul Amin ARM, Senga T, Oo ML, Thant AA, Hamaguchi M. Secretion of matrix metalloproteinase-9 by the proinflammatory cytokine, IL-1beta: A role for the dual signalling pathways, Akt and Erk. Genes to Cells 2003; 8: 515-23.
84. Yoo HG, Shin BA, Park JS et al. IL-1beta induces MMP-9 via reactive oxygen species and NF-kappaB in murine macrophage RAW 264.7 cells. Biochem Biophys Res Commun 2002; 298: 251-56.
85. Castrillo A, Joseph SB, Marathe C, Mangelsdorf DJ, Tontonoz P. Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages. J Biol Chem 2003; 278: 10443-49.
86. Jiang C. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-86.
87. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nature Med 2003; 9: 213-19.
88. Li M, Pascual G, Glass CK. Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. Molecular Cell Biol 2000; 20: 4699-707.
89. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J. Macrophages in human atheroma contain PPARgamma: Differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol 1998; 153: 17-23.
90. Arakawa R, Yokoyama S. Helical apolipoproteins stabilize ATP-binding cassette transporter A1 by protecting it from thiol protease-mediated degradation. J Biol Chem 2002; 277: 22426-29.
91. Oram JF, Lawn RM, Garvin MR, Wade DP. ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages. J Biol Chem 2000; 275: 34508-11.
92. Wang Y, Oram JF. Unsaturated fatty acids inhibit cholesterol efflux from macrophages by increasing degradation of ATP-binding cassette transporter A1. J Biol Chem 2002; 277: 5692-97.
93. Liao H, Langmann T, Schmitz G, Zhu Y. Native LDL upregulation of ATP-binding cassette transporter-1 in human vascular endothelial cells. Arterioscler Thromb Vasc Biol 2002; 22: 127-32.
94. Chawla A. nuclear receptors and lipid physiology: Opening the X-Files. Science 2001; 294: 1866-70.
95. Lu TT, Repa JJ, Mangelsdorf DJ. Orphan nuclear receptors as eLiXiRs and FiXeRs of sterol metabolism. J Biol Chem 2001; 276: 37735-38.
96. Wagner BL, Valledor AF, Shao G et al. Promoter-specific roles for liver X receptor/corepressor complexes in the regulation of ABCA1 and SREBP1 gene expression. Mol Cell Biol 2003; 23: 5780-89.
97. Fu X, Menke JG, Chen Y et al. 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J Biol Chem 2001; 276: 38378-87.
98. Repa JJ. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 2000; 289: 1524-29.
99. Venkateswaran A, Laffitte BA, Joseph SB et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc Natl Acad Sci U S A 2000; 97: 12097-102.
100. Joseph SB, McKilligin E, Pei L et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci U S A 2002; 99: 7604-09.
101. Tangirala RK, Bischoff ED, Joseph SB et al. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc Natl Acad Sci U S A 2002; 99: 11896-901.
102. Laffitte BA, Joseph SB, Walczak R et al. Autoregulation of the human liver X receptor alpha promoter. Mol Cell Biol 2001; 21: 7558-68.
103. Whitney KD, Watson MA, Goodwin B et al. Liver X receptor (LXR) regulation of the LXRalpha gene in human macrophages. J Biol Chem 2001; 276: 43509-15.
104. Chawla A, Boisvert WA, Lee CH et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 2001; 7: 161-71.
105. Chinetti G, Lestavel S, Bocher V et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001; 7: 53-58.
106. Uehara Y. Polyunsaturated fatty acids and acetoacetate downregulate the expression of the ATP-binding cassette transporter A1. Diabetes 2002; 51: 2922-28.
107. Ou J, Tu H, Shan B et al. Unsaturated fatty acids inhibit transcription of the sterol regulatory element-binding protein-1c (SREBP-1c) gene by antagonizing ligand-dependent activation of the LXR. Proc Natl Acad Sci U S A 2001; 98: 6027-32.
108. Wang Y, Kurdi-Haidar B, Oram JF. Liver X receptor-mediated activation of macrophage stearoyl-CoA desaturase generates unsaturated fatty acids that destabilize ATP-binding cassette transporter A1. J Lipid Res 2004; 45: 972-80.
109. Feng B, Tabas I. ABCA1-mediated cholesterol efflux is defective in free cholesterol-loaded macrophages: Mechanism involves enhanced ABCA1 degradation in a process requiring full NPC1 activity. J Biol Chem 2002; 277: 43271-80.
110. Martinez LO, Agerholm-Larsen B, Wang N, Chen W, Tall AR. Phosphorylation of a PEST sequence in ABCA1 promotes calpain degradation and is reversed by ApoA-l. J Biol Chem 2003; 278: 37368-74.
111. Yamauchi Y, Hayashi M, Abe-Dohmae S, Yokoyama S. Apolipoprotein A-I activates protein kinase C alpha signaling to phosphorylate and stabilize ATP binding cassette transporter A1 for the high density lipoprotein assembly. J Biol Chem 2003; 278: 47890-97.
112. Wang N, Chen W, Linsel-Nitschke P, Martinez L. A PEST sequence in ABCA1 regulates degradation by calpain protease and stabilization of ABCA1 by apoA-I. J Clin Invest 2003; 111: 99-107.
113. Oram JF, Wolfbauer G, Vaughan AM, Tang C, Albers JJ. Phospholipid transfer protein interacts with and stabilizes ATP-binding cassette transporter A1 and enhances cholesterol efflux from cells. J Biol Chem 2003; 278: 52379-85.
114. Albrecht C, Soumian S, Amey JS et al. ABCA1 expression in carotid atherosclerotic plaques. Stroke 2004; 35: 2801-06.
115. Cabrero A, Cubero M, Llaverias G et al. Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages. Metabolism 2003; 52: 652-57.
116. Sugimoto K, Tsujita M, Wu CA, Suzuki K, Yokoyama S. An inhibitor of acylCoA: cholesterol acyltransferase increases expression of ATP-binding cassette transporter A1 and thereby enhances the ApoA-I-mediated release of cholesterol from macrophages. Biochim Biophys Acta 2004; 1636: 69-76.
117. Guan JZ, Tamasawa N, Murakami H, Matsui J, Yamato K, Suda T. Clofibrate, a peroxisome-proliferator, enhances reverse cholesterol transport through cytochrome P450 activation and oxysterol generation. Tohoku J Exp Med 2003; 201: 251-59.
118. Suzuki S, Nishimaki-Mogami T, Tamehiro N et al. Verapamil increases the apolipoprotein-mediated release of cellular cholesterol by induction of ABCA1 expression via Liver X receptor-independent mechanism. Arterioscler Thromb Vasc Biol 2004; 24: 519-25.
119. Ando H, Tsuruoka S, Yamamoto H, Takamura T, Kaneko S, Fujimura A. Effects of pravastatin on the expression of ATP-binding cassette transporter A1. J Pharmacol Exp Ther 2004; 311: 420-25.
120. Athyros VG, Mikhailidis DP, Papageorgiou AA et al. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 2004; 20: 627-37.
121. Lewin AJ, Kipnes MS, Meneghini LF et al. Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 2004; 26: 379-89.
122. Maejima T, Yamazaki H, Aoki T et al. Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem Biophys Res Commun 2004; 324: 835-39.
123. Zanotti I, Favari E, Sposito AC, Rothblat GH, Bernini F. Pitavastatin increases ABCA1-mediated lipid efflux from Fu5AH rat hepatoma cells. Biochem Biophys Res Commun 2004; 321: 670-74.
124. Yoshikawa T, Shimano H, Amemiya-Kudo M et al. Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter. Mol Cell Biol 2001; 21: 2991-3000.
125. Arakawa R, Hayashi M, Remaley AT, Brewer BH, Yamauchi Y, Yokoyama S. Phosphorylation and stabilization of ATP binding cassette transporter A1 by synthetic amphiphilic helical peptides. J Biol Chem 2004; 279: 6217-20.
126. Natarajan P, Forte TM, Chu B, Phillips MC, Oram JF, Bielicki JK. Identification of an apolipoprotein A-I structural element that mediates cellular cholesterol efflux and stabilizes ATP binding cassette transporter A1. J Biol Chem 2004; 279: 24044-52.
127. Miao B, Zondlo S, Gibbs S et al. Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a s elective LXR modulator. J Lipid Res 2004; 45: 1410-17.